Ceuticoz Aims Rs 200 Crore Revenue By FY30, Targets 25-Country Footprint

Sukhbir Singh Chimni, Managing Director of Ceuticoz, is a seasoned business leader with extensive experience in the FMCG sector, particularly in personal care and F&B. Before leading Ceuticoz, he held key roles at The Coca-Cola Company, GSK Consumer, and Dabur, gaining expertise in brand management, sales, and business strategy.

An alumnus of the Faculty of Management Studies, University of Delhi, his strategic vision and innovative mindset positioned him to revolutionize the cosmeceuticals industry. With nearly two decades in skincare, in 2014, the Chandigarh-based Ceuticoz was founded to develop science-backed, medical-grade skincare solutions. The brand prioritizes research-driven formulations, stringent quality control, and dermatologist-recommended products.

He told Bizz Buzz in an exclusive interview that "its WHO-GMP and GLP-approved facility ensures excellence in production, utilizing advanced technologies and premium ingredients sourced from over 20 countries."

He said under his leadership, Ceuticoz has expanded across 100 distribution channels and gained endorsements from over 15,000 dermatologists. Over the years, Ceuticoz has positioned itself as a trusted name in global skincare. By bridging scientific research with consumer needs, he said they are continuing to shape the future of cosmeceuticals, inspiring aspiring entrepreneurs in the beauty and healthcare industry

How has the medical aesthetics and cosmeceuticals industry evolved in recent years?

The medical aesthetics and cosmeceuticals industry has seen significant evolution in recent years, driven by advancements in technology, growing consumer demand for non-invasive treatments, and a focus on personalized skincare. Innovations like AI-driven diagnostics, regenerative treatments (PRP, exosomes), and hybrid injectables have transformed the landscape. Additionally, the rise of clean beauty, biotech-infused skincare, and dermatologist-backed brands has fuelled market growth. Social media and influencer marketing continue to shape consumer preferences, making aesthetics more mainstream and accessible.

How do you see consumer preferences shifting towards science-backed and dermatology-led skincare?

Consumers are increasingly prioritizing science-backed and dermatology-led skincare, seeking proven efficacy over marketing hype. The demand for clinically tested ingredients like peptides, retinoids, and niacinamide has surged, with a strong preference for brands backed by dermatologists and scientific research. Transparency in formulations, minimalistic routines, and a focus on skin health over cosmetic trends are driving this shift. Additionally, personalized skincare powered by AI and biotech innovations is gaining traction, reinforcing the trust in medical-grade solutions.

What are Ceuticoz’s plans for expansion in India and international markets?

Ceuticoz, a dermo-cosmetic company, located in Chandigarh, with manufacturing facilities in Himachal Pradesh, and is part of Lyra Laboratories Pvt Ltd, is committed to strengthening its ethical market presence in India by becoming the preferred brand for clinical dermatology prescriptions. We are enhancing medical engagement, expanding into Tier 2 and 3 cities, and launching education-driven initiatives to build trust. Following the success of our Ivorine Brightening Range, we are diversifying into post-procedure skincare solutions.

Internationally, Ceuticoz is present in over 10 countries, with a strong foothold in Canada and ongoing expansion in the Middle East and Southeast Asia. Our vision is to establish Ceuticoz as a leading global Indian cosmeceutical brand—trusted by dermatologists, loved by patients, and backed by science.

Which new markets or regions is Ceuticoz aiming to enter in the coming year?

In the coming year, Ceuticoz is targeting the USA, UAE, and Saudi Arabia as key markets for expansion. These regions offer significant growth potential, with a rising demand for science-backed, dermatologist-recommended skincare products. We are actively working on establishing strategic partnerships with local distributors, skincare clinics, and dermatologists to strengthen our presence and build trust within these markets. Our goal is to position Ceuticoz as a leading choice in the global cosmeceutical space, offering high-quality, clinically proven skincare solutions to meet the diverse needs of consumers in these regions.

How does Ceuticoz differentiate itself from other cosmeceutical brands?

Ceuticoz is strategically differentiating itself from other cosmeceutical brands by combining clinical credibility, affordability, and Indian dermatological relevance—while gearing up for global competitiveness.

Every Ceuticoz product is clinically driven and dermatologically validated, designed to treat specific skin concerns like acne, pigmentation, sensitivity, and aging. We use evidence- based actives like Tranexamic Acid, Niacinamide, Peptides, Retinoids, and patented ingredients with proven results. There is a major emphasis on derma-grade efficacy, not just cosmetic appeal, i.e. bridging the gap between pharmaceuticals and skincare.

Ceuticoz operates at the intersection of clinical dermatology and modern skincare, creating solutions that doctors trust and patients love. We boast of strong in-clinic presence and medical engagement with dermatologists across India. Key Differentiator - Endorsed by dermatologists as both a treatment support and cosmetic enhancement, we offer medical-grade skincare at accessible prices, making science-backed skin health solutions available to a wider population. This is highly relevant in India and other developing markets, where price often limits access to clinical-grade skincare.

Ceuticoz stands apart by offering dermatologist-backed, medical-grade skincare that is affordable, ethical, and globally relevant—while being deeply rooted in Indian dermatology and scientific integrity

What is Ceuticoz’s current total revenue, and what is the projected revenue for FY26?

Ceuticoz’s projected India revenue for FY26 is Rs 50 crore. This growth is driven by our efforts to expand our product portfolio, strengthen market presence, and enter new regions, both domestically and internationally. Our focus on innovation, dermatologist collaborations, and community engagement will help achieve this target and ensure long-term growth.

Are there any upcoming product launches or R&D initiatives in the pipeline?

Yes, we are working to launch the paediatrics range with 7 products within the next few months. The formulation and packaging has been finalised for all the products and currently we have put them for clinical and consumer studies.

What are the company’s business goals for the next five years?

Ceuticoz’s India’s business targets for the next five years focus on achieving sustainable growth and expanding our global presence. We aim for a CAGR of 30–35 per cent, with a target revenue of Rs.150–200 crore by FY 2029-30, up from the current Rs 25–30 crore annual run rate.

Our strategy will be driven by ethical markets, product diversification, and global expansion. By FY 2030, we plan to derive 35–40 per cent of our revenue from international markets, with a presence in more than 25 countries. Additionally, we aim to build a network of 30,000+ prescribing dermatologists and cosmetologists to strengthen our market position and ensure continued success.